XFRA CAPITAL ADJUSTMENT INFORMATION

Realtime	Geld	Brief	Zeit
	4,860	5,000	08:54

Realtime

Geld

Brief

Zeit

4,860

5,000

08:54

XFRA CAPITAL ADJUSTMENT INFORMATION - 28.11.2023

Das Instrument 0N6A NL0015000YE1 TME PHARM.CONF.IPO EO-,01 EQUITY wird ex Kapitalmassnahme gehandelt am 28.11.2023
The instrument 0N6A NL0015000YE1 TME PHARM.CONF.IPO EO-,01 EQUITY is traded ex capital adjustment on 28.11.2023

Das Instrument SRC AU000000YOJ5 YOJEE LTD EQUITY wird cum Kapitalmassnahme gehandelt am 28.11.2023 und ex Kapitalmassnahme am 29.11.2023
The instrument SRC AU000000YOJ5 YOJEE LTD EQUITY is traded cum capital adjustment on 28.11.2023 and ex capital adjustment on 29.11.2023

Das Instrument RGI US7589321071 REGIS CORP. (MINN.) DL-05 EQUITY wird cum Kapitalmassnahme gehandelt am 28.11.2023 und ex Kapitalmassnahme am 29.11.2023
The instrument RGI US7589321071 REGIS CORP. (MINN.) DL-05 EQUITY is traded cum capital adjustment on 28.11.2023 and ex capital adjustment on 29.11.2023

Das Instrument MO8 JP3926800008 MORINAGA MILK IND. EQUITY wird cum Kapitalmassnahme gehandelt am 28.11.2023 und ex Kapitalmassnahme am 29.11.2023
The instrument MO8 JP3926800008 MORINAGA MILK IND. EQUITY is traded cum capital adjustment on 28.11.2023 and ex capital adjustment on 29.11.2023

Das Instrument K6X AU0000183253 LARVOTTO RESOURCES LTD. EQUITY wird cum Kapitalmassnahme gehandelt am 28.11.2023 und ex Kapitalmassnahme am 29.11.2023
The instrument K6X AU0000183253 LARVOTTO RESOURCES LTD. EQUITY is traded cum capital adjustment on 28.11.2023 and ex capital adjustment on 29.11.2023

Das Instrument JOHB BMG5150J1577 JOHNSON EL.HLDGS HD-,05 EQUITY wird cum Kapitalmassnahme gehandelt am 28.11.2023 und ex Kapitalmassnahme am 29.11.2023
The instrument JOHB BMG5150J1577 JOHNSON EL.HLDGS HD-,05 EQUITY is traded cum capital adjustment on 28.11.2023 and ex capital adjustment on 29.11.2023

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!

In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.

Hier klicken

Zeit	Aktuelle Nachrichten
Di	JOHNSON ELEC H (00179): DATE OF BOARD MEETING
06.03.	JOHNSON ELEC H (00179): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
06.03.	JOHNSON ELEC H (00179): APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF REMUNERATION COMMITTEE
17.01.	JOHNSON ELEC H (00179): NEXT DAY DISCLOSURE RETURN - CHANGES IN ISSUED SHARE CAPITAL
15.01.	JOHNSON ELEC H (00179): BUSINESS AND UNAUDITED FINANCIAL INFORMATION FOR THE THIRD QUARTER OF FINANCIAL YEAR 23/24

Zeit

Aktuelle Nachrichten

JOHNSON ELEC H (00179): DATE OF BOARD MEETING

06.03.

JOHNSON ELEC H (00179): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION

06.03.

JOHNSON ELEC H (00179): APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF REMUNERATION COMMITTEE

17.01.

JOHNSON ELEC H (00179): NEXT DAY DISCLOSURE RETURN - CHANGES IN ISSUED SHARE CAPITAL

15.01.

JOHNSON ELEC H (00179): BUSINESS AND UNAUDITED FINANCIAL INFORMATION FOR THE THIRD QUARTER OF FINANCIAL YEAR 23/24

Zeit	Aktuelle Nachrichten
Di	LARVOTTO RESOURCES LIMITED: Quarterly Activities/Appendix 5B Cash Flow Report
Mo	LARVOTTO RESOURCES LIMITED: Positive Processing Results from Hillgrove Gold Project
Mo	LARVOTTO RESOURCES LIMITED: Cleansing Statement
Mo	LARVOTTO RESOURCES LIMITED: Proposed issue of securities - LRV
Mo	LARVOTTO RESOURCES LIMITED: Application for quotation of securities - LRV

Zeit

Aktuelle Nachrichten

LARVOTTO RESOURCES LIMITED: Quarterly Activities/Appendix 5B Cash Flow Report

LARVOTTO RESOURCES LIMITED: Positive Processing Results from Hillgrove Gold Project

LARVOTTO RESOURCES LIMITED: Cleansing Statement

LARVOTTO RESOURCES LIMITED: Proposed issue of securities - LRV

LARVOTTO RESOURCES LIMITED: Application for quotation of securities - LRV

Zeit	Aktuelle Nachrichten
28.03.	Dividendenbekanntmachungen (28.03.2024)		Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACOM CO LTD JP3108600002 6 JPY 0,0366 EUR ADVANEX INC JP3213400009 20 JPY 0,1222 EUR AICA KOGYO CO LTD JP3100800006 59 JPY 0... ► Artikel lesen
28.11.23	XFRA CAPITAL ADJUSTMENT INFORMATION - 28.11.2023		Das Instrument 0N6A NL0015000YE1 TME PHARM.CONF.IPO EO-,01 EQUITY wird ex Kapitalmassnahme gehandelt am 28.11.2023 The instrument 0N6A NL0015000YE1 TME PHARM.CONF.IPO EO-,01 EQUITY is traded ex capital... ► Artikel lesen

Zeit

Aktuelle Nachrichten

28.03.

Dividendenbekanntmachungen (28.03.2024)

Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACOM CO LTD JP3108600002 6 JPY 0,0366 EUR ADVANEX INC JP3213400009 20 JPY 0,1222 EUR AICA KOGYO CO LTD JP3100800006 59 JPY 0...
► Artikel lesen

28.11.23

XFRA CAPITAL ADJUSTMENT INFORMATION - 28.11.2023

Zeit	Aktuelle Nachrichten
03:42	Earnings call: Regis Corporation reports modest sales growth, strategic focus
Mi	Regis Corp Q3 Loss Widens
Mi	Regis GAAP EPS of -$1.00, revenue of $49.2M
Mi	REGIS CORP - 10-Q, Quarterly Report
Mi	REGIS CORP - 8-K, Current Report

Zeit

Aktuelle Nachrichten

03:42

Earnings call: Regis Corporation reports modest sales growth, strategic focus

Regis Corp Q3 Loss Widens

Regis GAAP EPS of -$1.00, revenue of $49.2M

REGIS CORP - 10-Q, Quarterly Report

REGIS CORP - 8-K, Current Report

Zeit	Aktuelle Nachrichten
25.04.	TME Pharma Publishes 2023 Financial Results and Provides Operating Update	Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds, terminating the convertible bond program Cash consumption reduced... ► Artikel lesen
23.04.	TME Pharma N.V.: TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer	Two of six patients receiving NOX-A12 in combination with bevacizumab and radiotherapy exceeded 24-month survival since the start of therapy This survival compares favorably to the 5% survival... ► Artikel lesen
02.04.	TME Pharma N.V.: TME Pharma Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer	Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in glioblastoma and could support an accelerated pathway to US regulatory... ► Artikel lesen
28.03.	TME Pharma N.V.: TME Pharma Provides Results of First Exercise of Warrants Z	479,624 Warrants Z were exercised resulting in the issuance of 599,530 new ordinary shares Outstanding 3,326,104 Warrants Z remain exercisable until June 20, 2025, with potential to raise... ► Artikel lesen
05.03.	TME Pharma N.V.: TME Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for NOX-A12 Phase 2 Trial in Brain Cancer	Clinical trial protocol approved in the US to initiate Phase 2 study with NOX-A12 in glioblastoma providing a clear roadmap for clinical development to investors and potential partners ... ► Artikel lesen

Zeit

Aktuelle Nachrichten

25.04.

TME Pharma Publishes 2023 Financial Results and Provides Operating Update

Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds, terminating the convertible bond program Cash consumption reduced...
► Artikel lesen

23.04.

TME Pharma N.V.: TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer

Two of six patients receiving NOX-A12 in combination with bevacizumab and radiotherapy exceeded 24-month survival since the start of therapy This survival compares favorably to the 5% survival...
► Artikel lesen

02.04.

TME Pharma N.V.: TME Pharma Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer

Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in glioblastoma and could support an accelerated pathway to US regulatory...
► Artikel lesen

28.03.

TME Pharma N.V.: TME Pharma Provides Results of First Exercise of Warrants Z

479,624 Warrants Z were exercised resulting in the issuance of 599,530 new ordinary shares Outstanding 3,326,104 Warrants Z remain exercisable until June 20, 2025, with potential to raise...
► Artikel lesen

05.03.

TME Pharma N.V.: TME Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for NOX-A12 Phase 2 Trial in Brain Cancer

Clinical trial protocol approved in the US to initiate Phase 2 study with NOX-A12 in glioblastoma providing a clear roadmap for clinical development to investors and potential partners ...
► Artikel lesen

Zeit	Aktuelle Nachrichten
Di	YOJEE LIMITED: Quarterly Activities Report & Appendix 4C - Mar 2024
23.04.	YOJEE LIMITED: Yojee Signs Agreement with APP in Indonesia
23.04.	YOJEE LIMITED: Notification of cessation of securities - YOJ
17.04.	YOJEE LIMITED: Becoming a substantial holder
16.04.	YOJEE LIMITED: Change of Director's Interest Notice

Zeit

Aktuelle Nachrichten

YOJEE LIMITED: Quarterly Activities Report & Appendix 4C - Mar 2024

23.04.

YOJEE LIMITED: Yojee Signs Agreement with APP in Indonesia

23.04.

YOJEE LIMITED: Notification of cessation of securities - YOJ

17.04.

YOJEE LIMITED: Becoming a substantial holder

16.04.

YOJEE LIMITED: Change of Director's Interest Notice

Unternehmen / Aktien	Kurs	%
JOHNSON ELECTRIC HOLDINGS LTD	1,270	0,00 %
LARVOTTO RESOURCES LIMITED	0,041	0,00 %
MORINAGA MILK INDUSTRY CO LTD	18,000	+0,56 %
REGIS CORPORATION	5,200	0,00 %
TME PHARMA NV	0,255	0,00 %
YOJEE LIMITED	0,022	+4,88 %

Unternehmen / Aktien

Kurs

JOHNSON ELECTRIC HOLDINGS LTD

1,270

0,00 %

LARVOTTO RESOURCES LIMITED

0,041

0,00 %

MORINAGA MILK INDUSTRY CO LTD

18,000

+0,56 %

REGIS CORPORATION